Trial reportJournal of thrombosis and thrombolysis2014
Statins, aspirin and risk of venous thromboembolic events in breast cancer patients.
Trial report in Journal of thrombosis and thrombolysis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Statins for the primary prevention of venous thromboembolism.The Cochrane database of systematic reviews · 2024Pooled it
- No evidence for a genetic causal effect of breast cancer on venous thromboembolism: a mendelian randomization study.Journal of thrombosis and thrombolysis · 2024Pooled it
- The role of statins in mitigating venous thromboembolism incidence and severity.Research and practice in thrombosis and haemostasis · 2025Article
- A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.Cancers · 2023Article
- Risk factors associated with venous thromboembolism in breast cancer: a narrative review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022Review
- Statins can benefit patients with primary membranous nephropathy on venous thromboembolism.Renal failure · 2021Article
- Cancer-Associated Atherothrombosis: The Challenge.The International journal of angiology : official publication of the International College of Angiology, Inc · 2021Review
- The Enhanced Cytotoxic and Pro-Apoptotic Effects of Optimized Simvastatin-Loaded Emulsomes on MCF-7 Breast Cancer Cells.Pharmaceutics · 2020Article
- Article
- The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy.Renal failure · 2019Article
- Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p.Aging · 2019Article
- Statins as a preventative therapy for venous thromboembolism.Cardiovascular diagnosis and therapy · 2017Review
- Review
- Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice.Journal of thrombosis and haemostasis : JTH · 2016Article
- Venous thrombosis and cancer: from mouse models to clinical trials.Journal of thrombosis and haemostasis : JTH · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolic events (VTE's) are associated with decreased survival in breast cancer patients. Studies suggested that statins reduce the risk of VTE's in the general population. Low dose Aspirin reduces risk of VTE's in high risk populations. The Breast Cancer in Northern Israel Study is a case-control study of consecutive breast cancer cases diagnosed in northern Israel and matched controls. The present analysis was limited to cases with breast cancer enrolled in the study. Data was extracted from Clalit Health Services (CHS) database and from computerized pharmacy records. Out of 3,585 patients enrolled, 261 (7.3%) had a VTE during median follow up of 4.2 years. The 1 and 2 year cumulative incidence was 2.64 and 3.65%. 55.7% of patients used statins, predominantly simvastatin (75.8%). 44.5% used aspirin. In multivariate analysis neither statins nor aspirin use was associated with a reduced risk for a VTE. Unadjusted HR for statin and aspirin was 1.461 (1.018-2.096) and 1.293 (0.846-1.976), respectively, and the adjusted HR were 0.86 (0.648-1.14) and 1.013 (0.737-1.392). Results were similar when only simvastatin use was assessed. Metastatic disease, chemotherapy, age, BMI and presence of comorbidities were significantly associated with risk of VTE's. Our study is the first to look at the effect of statins and aspirin on the incidence of VTE's in patients with breast cancer. In our cohort, statin and aspirin use did not decrease the risk for a VTE. Our results might be explained by use of low potency statins (simvastatin and pravastatin) and by alternate mechanisms for VTE formation in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.